Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma

NCT05833893 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.

NCT NCT05833893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05833893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Lead sponsor
Chinese PLA General Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
May 1, 2023
Completion date
December 31, 2026
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced lymphoma, newly diagnosed, nk/t-cell lymphoma